Role of bone scan in newly diagnosed breast cancer patients in Erbil City
DOI:
https://doi.org/10.61841/5e28g935Keywords:
diagnosed breast cancer, retrospective study, Erbil cityAbstract
Background and objectives: It is necessary to highlight the importance of general nuclear medicine in the care of women with breast cancer including detection, classification and treatment guidance, accordingly this study was conducted to investigate the role of bone scan among newly diagnosed breast cancer patients and to find out the relationship between some clinico-pathological variables and bone metastasis.
Methodology: This retrospective study was done in Nuclear Medicine unit- the radiological department of Hawler teaching hospital in Erbil City in which 40 confirmed breast cancer cases referred from various hospitals in Erbil were included in the study. Statistical Package for Social Science was used for the purpose of data analysis.
Results: The age of breast cancer patients ranged from 26 to 59 years, with a mean age ± SD of 44.8 ±8.88 years. The majority (90%) were clinically presented with signs of a lump in the breasts. 62.5% of them had lymph node involvement, and the majority (95.0%) showed ductal carcinoma. Abnormal bone scan findings were identified among 42.5% of them, especially among those with stage II, advanced age, more lymph node involvement, and a sensitivity of 47.0%, and specificity of 60.9%. Multiple skeletal metastases were found most commonly in the ribs and lower limbs (67.0% and 64%, respectively).Most of the socio-demographic and clinical factors revealed non-definitive associations with the bone scan findings.
Conclusions: The quality of the imaging findings was not encouraging, because of relatively low sensitivity and specificity, accordingly for each patient; the right investigative technique should be selected individually, taking into consideration different clinico-pathological features of the patients.
Downloads
References
1. Zekri J, Farag K. Assessment of bone health in breast cancer patients starting adjuvant aromatase inhibitors: A quality improvement clinical audit. J Bone Oncol 2016; 5 (4):159- 62.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Ca Cancer J Clin 2015; 65: 87-108.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 2018; 0:1-31.
4. Greene LR, Wilkinson D. The role of general nuclear medicine in breast cancer. J Med Radiat Sci 2015; 62:54-65.
5. Fengyu Wu, Jiang Y, Ma L, Yu Q, Xue W, Wang Z. Detection of bone metastases in patients with cancer: 99mTc-MDP bone scan and 18F-FDG PET/CT. Biomed Res 2017; 28 (3):1299-304.
6. O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. World J Radiol 2015; 7(8):202-11.
7. Sifat T, Begum F, Sultana S, Mutsuddy P, Naznin A, Begum SM. Frequency and site of skeletal metastatic lesion detected by bone scintigraphy in newly diagnosed asymptomatic cancer patients. Bangladesh J Nucl Med 2017; 20(1):18-4.
8. Heindel W, Gübitz R, Vieth V, Weckesser M, Schober O, Schäfers M. The diagnostic imaging of bone metastases. Dtsch Arztebl Int 2014; 111:741-7.
9. Vassiliou V, Andreopoulos D, Frangos S, Tselis N, Giannopoulou E, Lutz S. Bone metastases: assessment of therapeutic response through radiological and nuclear medicine imaging modalities. Clin Oncol (R Coll Radiol) 2011; 23:632-45.
10. Sharmin S, Haque JA, Rahman M, Rahman HA, Hossain J, Uddin M, et al. Correlation between Bone Scan Findings and CA 15-3 in Patients with Carcinoma Breast. Bangladesh J Nucl Med 2017; 20 (1):24- 6.
11. Koizumi M, Yoshimoto M, Kasumi F, Ogata E. What do breast cancer patients benefit from static bone scintigraphy? Jpn J Clin Oncol 2001; 31:263-9.
12. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-93.
13. Al- Naqqash MA, Al- Bdaer EK, Saleh WA, Al- Shewered AS. Progression free survival in Iraqi breast cancer patients treated with adjuvant 3D conformal radiotherapy: A cross-sectional study. F1000 Research 2019; 8:1-10.
14. De Cesare A, De Vincentis G, Gervasi S, Crescentini G, Fiori E, Bonomi M, et al. Single-photon-emission computed tomography (SPECT) with technetium-99m sestamibi in the diagnosis of small breast cancer and axillary lymph node involvement. World J Surg 2011; 35(12):2668-72.
15. Oussama MNK: Guidelines for the early detection and screening of breast cancer. EMRO. Technical Publications Series 30. WHO; 2006.
16. Caglar M, Kupik O, Karabulut E, Høilund-Carlsen PF. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?Rev Esp Med Nucl Imagen Mol 2016; 35(1):3- 11.
17. American Cancer Society. Breast Cancer Facts & Figures 1. 2009-2010. Atlanta: American Cancer Society; 2012.
18. Al-Khafaji AH. Immunohisto- chemical expression 10 of Estrogen, Progesterone receptors, P53 and Ki67 in Iraqi and Syrian breast cancer patients, A clinic-pathological study. Baghdad-Iraq; 2010.
19. Pulido C, Vendrell I, Ferreira AR, Casimiro S, Mansinho A, Alho I, et al. Bonemetastasis risk factors in breast cancer. Ecancermedicalscience 2017, 11:715 DOI: 10.3332/ecancer.2017.715.
20. Helton LA, Garcia FL, Simionato LC, Matthes AC, Bighetti S. Correlation between clinical staging and skeletal alterations of bone metastases in breast cancer patients. Acta Ortop Bras 2001; 9(1):21-8.
21. Chen WZ, Shen JF, Zhou Y, Chen XY, Liu JM, Liu ZL. Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer. Sci Rep 2017; 7:1-7.
22. Lee JE, Park SS, Han W, Kim SW, Shin HJ, Choe KJ, et al. The clinical use of staging bone scan in patients with breast carcinoma: reevaluation by the 2003 American Joint Committee on Cancer staging system. Cancer 2005; 104(3):499-503.
23. Yazdani A, Dorri S, Atashi A, Shirafkan H, Zabolinezhad H. Bone Metastasis Prognostic Factors in Breast Cancer. Breast Cancer (Auckl) 2019; 13:1-7.
24. Hurley C, Mc Carville B, Shulkin BL, Mao S, Wu J, Navid F, et al. Comparison of 18F-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma. Pediatr Blood Cancer 2016; 63(8):1381-6.
25. Yamashiro H, Takada M, Nakatani E, Imai S, Yamauchi A, Tsuyuki S, et al. Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan. Int J Clin Oncol 2014; 19(5):852-62.
26. Al-Rawaq KJ, Al-Naqqash MA, Jassim MK. Molecular classification of Iraqi breast cancer patients and its correlation with patients’ profile. J Fac Med Baghdad 2016; 58(3):1-5.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
